Metrion Biosciences’ CEO Dr Andrew Southan presents an overview of Metrion Biosciences, highlighting the company’s vision, expertise and services. December 10th, 2020.

Marc Rogers (Metrion CSO) presents a talk at the Nanion Virtual User Meeting 2020 entitled “Designing multiple assay protocols for ligand-gated ion channels using the stacked-tip feature on the Patchliner and SP384i platforms”. 14th October 2020.

Marc Rogers (Metrion CSO) takes part in a collaborative webinar with Nanion Technologies entitled “Validation and optimization of automated patch-clamp voltage-gated Ca2+ channel assays”.

As part of the the LabTube meets series of interviews Marc Rogers, Metrion Biosciences CSO, outlines the benefits of targeting ion channels for pain and some of the hurdles in developing successful ion channel modulators.

Presentation by Marc Rogers (Metrion CSO) at the 8th February 2018 SR Live event during Metrion’s 2018 Syndicate Room finance round.

Presentation by Marc Rogers (Metrion CSO) at the June 2016 Sophion Ion Channel Modulation Symposium, Clare College, Cambridge (UK). CiPA update: in vitro cardiac ion channel screens, in silico models and stem cell iPS cardiomyocyte assays for proarrhythmia risk prediction.

Presentation by Marc Rogers (Metrion CSO) at the September 2015 Safety Pharmacological Society, Prague. Using high quality HTS automated patch-clamp data from human cardiac ion channels and in silico action potential modelling to cost-effectively predict QP prolongation and arrhythmia risk for CiPA.